Smouldering-Associated Worsening in Multiple Sclerosis: An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions.
Journal
Annals of neurology
ISSN: 1531-8249
Titre abrégé: Ann Neurol
Pays: United States
ID NLM: 7707449
Informations de publication
Date de publication:
25 Jul 2024
25 Jul 2024
Historique:
revised:
03
07
2024
received:
04
03
2024
accepted:
05
07
2024
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
25
7
2024
Statut:
aheadofprint
Résumé
Despite therapeutic suppression of relapses, multiple sclerosis (MS) patients often experience subtle deterioration, which extends beyond the definition of "progression independent of relapsing activity." We propose the concept of smouldering-associated-worsening (SAW), encompassing physical and cognitive symptoms, resulting from smouldering pathological processes, which remain unmet therapeutic targets. We provide a consensus-based framework of possible pathological substrates and manifestations of smouldering MS, and we discuss clinical, radiological, and serum/cerebrospinal fluid biomarkers for potentially monitoring SAW. Finally, we share considerations for optimizing disease surveillance and implications for clinical trials to promote the integration of smouldering MS into routine practice and future research efforts. ANN NEUROL 2024.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Sanofi
Informations de copyright
© 2024 The Author(s). Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Références
Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014;83:278–286.
Tur C, Carbonell‐Mirabent P, Cobo‐Calvo Á, et al. Association of early progression independent of relapse activity with long‐term disability after a first demyelinating event in multiple sclerosis. JAMA Neurol 2023;80:151–160.
Lublin FD, Häring DA, Ganjgahi H, et al. How patients with multiple sclerosis acquire disability. Brain 2022;145:3147–3161.
Kuhlmann T, Moccia M, Coetzee T, et al. Multiple sclerosis progression: time for a new mechanism‐driven framework. Lancet Neurol 2023;22:78–88.
Oh J, Bar‐Or A. Emerging therapies to target CNS pathophysiology in multiple sclerosis. Nat Rev Neurol 2022;18:466–475.
Giovannoni G, Popescu V, Wuerfel J, et al. Smouldering multiple sclerosis: the ‘real MS’. Ther Adv Neurol Disord 2022;15:17562864211066752.
Kurtzke JF. A new scale for evaluating disability in multiple sclerosis. Neurology 1955;5:580–583.
Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of relapse‐independent progression vs relapse‐associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol 2020;77:1132–1140.
Fischer JS, Rudick RA, Cutter GR, et al. The multiple sclerosis functional composite measure (MSFC): an integrated approach to MS clinical outcome assessment. Mult Scler J 1999;5:244–250.
Kalincik T, Vivek V, Jokubaitis V, et al. Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain 2013;136:3609–3617.
Scalfari A. MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses – yes. Mult Scler 2021;27:1002–1004.
Portaccio E, Bellinvia A, Fonderico M, et al. Progression is independent of relapse activity in early multiple sclerosis: a real‐life cohort study. Brain 2022;145:2796–2805.
Cadavid D, Cohen JA, Freedman MS, et al. The EDSS‐plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. Mult Scler 2017;23:94–105.
Sinay V, Perez Akly M, Zanga G, et al. School performance as a marker of cognitive decline prior to diagnosis of multiple sclerosis. Mult Scler 2015;21:945–952.
Oh J, Suthiphosuwan S, Sati P, et al. Cognitive impairment, the central vein sign, and paramagnetic rim lesions in RIS. Mult Scler 2021;27:2199–2208.
Feuillet L, Reuter F, Audoin B, et al. Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 2007;13:124–127.
Oliva Ramirez A, Keenan A, Kalau O, et al. Prevalence and burden of multiple sclerosis‐related fatigue: a systematic literature review. BMC Neurol 2021;21:468.
Weiland TJ, De Livera AM, Brown CR, et al. Health outcomes and lifestyle in a sample of people with multiple sclerosis (HOLISM): longitudinal and validation cohorts. Front Neurol 2018;9:1074.
Wang G, Marrie RA, Fox RJ, et al. Treatment satisfaction and bothersome bladder, bowel, sexual symptoms in multiple sclerosis. Mult Scler Relat Disord 2018;20:16–21.
Patten SB, Marrie RA, Carta MG. Depression in multiple sclerosis. Int Rev Psychiatry 2017;29:463–472.
Sheridan CJ, Bowditch M. A case of intermittent exercise‐induced foot drop in a recreational runner. Clin J Sport Med 2020;30:e169–e171.
Tahedl M, Levine SM, Greenlee MW, et al. Functional connectivity in multiple sclerosis: recent findings and future directions. Front Neurol 2018;9:828.
Schoonheim MM, Broeders TAA, Geurts JJG. The network collapse in multiple sclerosis: an overview of novel concepts to address disease dynamics. Neuroimage Clin 2022;35:103108.
Absinta M, Maric D, Gharagozloo M, et al. A lymphocyte‐microglia‐astrocyte axis in chronic active multiple sclerosis. Nature 2021;597:709–714.
Frischer JM, Weigand SD, Guo Y, et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol 2015;78:710–721.
Ponath G, Ramanan S, Mubarak M, et al. Myelin phagocytosis by astrocytes after myelin damage promotes lesion pathology. Brain 2017;140:399–413.
Howell OW, Reeves CA, Nicholas R, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 2011;134:2755–2771.
Magliozzi R, Howell OW, Reeves C, et al. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol 2010;68:477–493.
International Multiple Sclerosis Genetics Consortium, MultipleMS Consortium. Locus for severity implicates CNS resilience in progression of multiple sclerosis. Nature 2023;619:323–331.
Jokubaitis VG, Campagna MP, Ibrahim O, et al. Not all roads lead to the immune system: the genetic basis of multiple sclerosis severity. Brain 2023;146:2316–2331.
Machado‐Santos J, Saji E, Tröscher AR, et al. The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue‐resident CD8+ T lymphocytes and B cells. Brain 2018;141:2066–2082.
Liddelow SA, Guttenplan KA, Clarke LE, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 2017;541:481–487.
Trapp BD, Stys PK. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 2009;8:280–291.
De Barcelos IP, Troxell RM, Graves JS. Mitochondrial dysfunction and multiple sclerosis. Biology 2019;8:37. https://doi.org/10.3390/biology8020037.
Holman SP, Lobo AS, Novorolsky RJ, et al. Neuronal mitochondrial calcium uniporter deficiency exacerbates axonal injury and suppresses remyelination in mice subjected to experimental autoimmune encephalomyelitis. Exp Neurol 2020;333:113430.
Elkjaer ML, Hartebrodt A, Oubounyt M, et al. Single‐cell multi‐omics map of cell type‐specific mechanistic drivers of multiple sclerosis lesions. Neurol Neuroimmunol Neuroinflamm 2024;11:e200213.
Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005;128:2705–2712.
Werneburg S, Jung J, Kunjamma RB, et al. Targeted complement inhibition at synapses prevents microglial synaptic engulfment and synapse loss in demyelinating disease. Immunity 2020;52:167–182.e7.
Magliozzi R, Howell O, Vora A, et al. Meningeal B‐cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007;130:1089–1104.
Illes Z, Jørgensen MM, Bæk R, et al. New enhancing MRI lesions associate with IL‐17, neutrophil degranulation and integrin microparticles: multi‐omics combined with frequent MRI in multiple sclerosis. Biomedicines 2023;11:3170. https://doi.org/10.3390/biomedicines11123170.
Havrdová E, Belova A, Goloborodko A, et al. Activity of secukinumab, an anti‐IL‐17A antibody, on brain lesions in RRMS: results from a randomized, proof‐of‐concept study. J Neurol 2016;263:1287–1295.
Smolders J, Heutinck KM, Fransen NL, et al. Tissue‐resident memory T cells populate the human brain. Nat Commun 2018;9:4593.
Luchetti S, Fransen NL, vanEden CG, et al. Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis. Acta Neuropathol 2018;135:511–528.
Ramesh A, Schubert RD, Greenfield AL, et al. A pathogenic and clonally expanded B cell transcriptome in active multiple sclerosis. Proc Natl Acad Sci U S A 2020;117:22932–22943.
Schafflick D, Xu CA, Hartlehnert M, et al. Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis. Nat Commun 2020;11:247.
Wheeler MA, Clark IC, Tjon EC, et al. MAFG‐driven astrocytes promote CNS inflammation. Nature 2020;578:593–599.
Clark IC, Gutiérrez‐Vázquez C, Wheeler MA, et al. Barcoded viral tracing of single‐cell interactions in central nervous system inflammation. Science 2021;372:eabf1230. https://doi.org/10.1126/science.abf1230.
Scalfari A, Lederer C, Daumer M, et al. The relationship of age with the clinical phenotype in multiple sclerosis. Mult Scler 2016;22:1750–1758.
Graves JS, Krysko KM, Hua LH, et al. Ageing and multiple sclerosis. Lancet Neurol 2023;22:66–77.
Cole JH, Raffel J, Friede T, et al. Longitudinal assessment of multiple sclerosis with the brain‐age paradigm. Ann Neurol 2020;88:93–105.
Vollmer TL, Nair KV, Williams IM, Alvarez E. Multiple sclerosis phenotypes as a continuum: the role of neurologic reserve. Neurol Clin Pract 2021;11:342–351.
Sim FJ, Zhao C, Penderis J, Franklin RJM. The age‐related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation. J Neurosci 2002;22:2451–2459.
Bühring J, Hecker M, Fitzner B, Zettl UK. Systematic review of studies on telomere length in patients with multiple sclerosis. Aging Dis 2021;12:1272–1286.
Hecker M, Bühring J, Fitzner B, et al. Genetic, environmental and lifestyle determinants of accelerated telomere attrition as contributors to risk and severity of multiple sclerosis. Biomolecules 2021;11:1510. https://doi.org/10.3390/biom11101510.
Kular L, Klose D, Urdánoz‐Casado A, et al. Epigenetic clock indicates accelerated aging in glial cells of progressive multiple sclerosis patients. Front Aging Neurosci 2022;14:926468.
Jurga AM, Paleczna M, Kadluczka J, Kuter KZ. Beyond the GFAP‐astrocyte protein markers in the brain. Biomolecules 2021;11:1316. https://doi.org/10.3390/biom11091361.
Spittau B. Aging microglia‐phenotypes, functions and implications for age‐related neurodegenerative diseases. Front Aging Neurosci 2017;9:194.
McNamara NB, Munro DAD, Bestard‐Cuche N, et al. Microglia regulate central nervous system myelin growth and integrity. Nature 2023;613:120–129.
Marrie RA, Reider N, Cohen J, et al. A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. Mult Scler 2015;21:318–331.
Manouchehrinia A, Westerlind H, Kingwell E, et al. Age related multiple sclerosis severity score: disability ranked by age. Mult Scler 2017;23:1938–1946.
Disanto G, Barro C, Benkert P, et al. Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol 2017;81:857–870.
Barro C, Benkert P, Disanto G, et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain 2018;141:2382–2391.
Kuhle J, Kropshofer H, Haering DA, et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology 2019;92:e1007–e1015.
Bar‐Or A, Thanei G‐A, Harp C, et al. Blood neurofilament light levels predict non‐relapsing progression following anti‐CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double‐blind phase 3 clinical trials. EBioMedicine 2023;93:104662.
Maggi P, Kuhle J, Schädelin S, et al. Chronic white matter inflammation and serum neurofilament levels in multiple sclerosis. Neurology 2021;97:e543–e553.
Absinta M, Sati P, Masuzzo F, et al. Association of chronic active multiple sclerosis lesions with disability in vivo. JAMA Neurol 2019;76:1474–1483.
Yang Z, Wang KKW. Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci 2015;38:364–374.
Meier S, Willemse EAJ, Schaedelin S, et al. Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis. JAMA Neurol 2023;80:287–297.
Högel H, Rissanen E, Barro C, et al. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity. Mult Scler 2020;26:210–219.
Jiang X, Shen C, Teunissen CE, et al. Glial fibrillary acidic protein and multiple sclerosis progression independent of acute inflammation. Mult Scler 2023;29:1070–1079.
Floro S, Carandini T, Pietroboni AM, et al. Role of chitinase 3‐like 1 as a biomarker in multiple sclerosis: a systematic review and meta‐analysis. Neurol Neuroimmunol Neuroinflamm 2022;9:e1164. https://doi.org/10.1212/NXI.0000000000001164.
Elkjaer ML, Nawrocki A, Kacprowski T, et al. CSF proteome in multiple sclerosis subtypes related to brain lesion transcriptomes. Sci Rep 2021;11:4132.
Comabella M, Clarke MA, Schaedelin S, et al. CSF chitinase 3‐like 1 is associated with iron rims in patients with a first demyelinating event. Mult Scler 2022;28:71–81.
Magliozzi R, Scalfari A, Pisani AI, et al. The CSF profile linked to cortical damage predicts multiple sclerosis activity. Ann Neurol 2020;88:562–573.
Zhang Q, Jiang J, Liu Y, et al. Activated microglia promote invasion and barrier dysfunction of brain endothelial cells via regulating the CXCL13/CXCR5 axis. Cell Biol Int 2022;46:1510–1518.
Mailand MT, Frederiksen JL. Intrathecal IgM as a prognostic marker in multiple sclerosis. Mol Diagn Ther 2020;24:263–277.
Rosenstein I, Rasch S, Axelsson M, et al. Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing‐remitting multiple sclerosis. Front Immunol 2022;13:967953.
Barkhof F. The clinico‐radiological paradox in multiple sclerosis revisited. Curr Opin Neurol 2002;15:239–245.
Elliott C, Wolinsky JS, Hauser SL, et al. Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions. Mult Scler 2019;25:1915–1925.
Bagnato F, Sati P, Hemond CC, et al. Imaging chronic active lesions in multiple sclerosis: a consensus statement. Brain 2024;awae013. https://doi.org/10.1093/brain/awae013.
Elliott C, Rudko DA, Arnold DL, et al. Lesion‐level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis. Mult Scler 2023;29:680–690.
Calvi A, Carrasco FP, Tur C, et al. Association of slowly expanding lesions on MRI with disability in people with secondary progressive multiple sclerosis. Neurology 2022;98:e1783–e1793.
Klistorner S, Barnett MH, Yiannikas C, et al. Expansion of chronic lesions is linked to disease progression in relapsing–remitting multiple sclerosis patients. Mult Scler 2021;27:1533–1542.
Calvi A, Clarke MA, Prados F, et al. Relationship between paramagnetic rim lesions and slowly expanding lesions in multiple sclerosis. Mult Scler 2023;29:352–362.
Preziosa P, Pagani E, Meani A, et al. Slowly expanding lesions predict 9‐year multiple sclerosis disease progression. Neurol Neuroimmunol Neuroinflamm 2022;9:e1139. https://doi.org/10.1212/NXI.0000000000001139.
Bagnato F, Hametner S, Yao B, et al. Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 tesla. Brain 2011;134:3602–3615.
Kaunzner UW, Kang Y, Zhang S, et al. Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions. Brain 2019;142:133–145.
Dal‐Bianco A, Grabner G, Kronnerwetter C, et al. Long‐term evolution of multiple sclerosis iron rim lesions in 7 T MRI. Brain 2021;144:833–847.
Clarke MA, Cheek R, Kazimuddin HF, et al. Paramagnetic rim lesions and the central vein sign: characterizing multiple sclerosis imaging markers. J Neuroimaging 2024;34:86–94.
Dal‐Bianco A, Grabner G, Kronnerwetter C, et al. Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging. Acta Neuropathol 2017;133:25–42.
Clark KA, Manning AR, Chen L, et al. Early magnetic resonance imaging features of new paramagnetic rim lesions in multiple sclerosis. Ann Neurol 2023;94:736–744.
Galbusera R, Bahn E, Weigel M, et al. Characteristics, prevalence, and clinical relevance of Juxtacortical paramagnetic rims in patients with multiple sclerosis. Neurology 2024;102:e207966.
Huang W, Sweeney EM, Kaunzner UW, et al. Quantitative susceptibility mapping versus phase imaging to identify multiple sclerosis iron rim lesions with demyelination. J Neuroimaging 2022;32:667–675.
Airas L, Yong VW. Microglia in multiple sclerosis ‐ pathogenesis and imaging. Curr Opin Neurol 2022;35:299–306.
Giannetti P, Politis M, Su P, et al. Increased PK11195‐PET binding in normal‐appearing white matter in clinically isolated syndrome. Brain 2015;138:110–119.
Rissanen E, Tuisku J, Vahlberg T, et al. Microglial activation, white matter tract damage, and disability in MS. Neurol Neuroimmunol Neuroinflamm 2018;5:e443.
Saraste M, Matilainen M, Vuorimaa A, et al. Association of serum neurofilament light with microglial activation in multiple sclerosis. J Neurol Neurosurg Psychiatry 2023;94:698–706.
Hamzaoui M, Garcia J, Boffa G, et al. Positron emission tomography with [18F]‐DPA‐714 unveils a smoldering component in most multiple sclerosis lesions which drives disease progression. Ann Neurol 2023;94:366–383.
Sucksdorff M, Matilainen M, Tuisku J, et al. Brain TSPO‐PET predicts later disease progression independent of relapses in multiple sclerosis. Brain 2020;143:3318–3330.
Schmidt S, Isaak A, Junker A. Spotlight on P2X7 receptor PET imaging: a bright target or a failing star? Int J Mol Sci 2023;24:1374. https://doi.org/10.3390/ijms24021374.
Calabrese M, Poretto V, Favaretto A, et al. Cortical lesion load associates with progression of disability in multiple sclerosis. Brain 2012;135:2952–2961.
Calabrese M, De Stefano N, Atzori M, et al. Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch Neurol 2007;64:1416–1422.
Scalfari A, Romualdi C, Nicholas RS, et al. The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis. Neurology 2018;90:e2107–e2118.
Haider L, Prados F, Chung K, et al. Cortical involvement determines impairment 30 years after a clinically isolated syndrome. Brain 2021;144:1384–1395.
Ziccardi S, Pisani AI, Schiavi GM, et al. Cortical lesions at diagnosis predict long‐term cognitive impairment in multiple sclerosis: a 20‐year study. Eur J Neurol 2023;30:1378–1388.
Seyedmirzaei H, Nabizadeh F, Aarabi MH, Pini L. Neurite orientation dispersion and density imaging in multiple sclerosis: a systematic review. J Magn Reson Imaging 2023;58:1011–1029.
Preziosa P, Pagani E, Bonacchi R, et al. In vivo detection of damage in multiple sclerosis cortex and cortical lesions using NODDI. J Neurol Neurosurg Psychiatry 2022;93:628–636.
Collorone S, Cawley N, Grussu F, et al. Reduced neurite density in the brain and cervical spinal cord in relapsing‐remitting multiple sclerosis: a NODDI study. Mult Scler 2020;26:1647–1657.
Fisniku LK, Chard DT, Jackson JS, et al. Gray matter atrophy is related to long‐term disability in multiple sclerosis. Ann Neurol 2008;64:247–254.
Cagol A, Schaedelin S, Barakovic M, et al. Association of brain atrophy with disease progression independent of relapse activity in patients with relapsing multiple sclerosis. JAMA Neurol 2022;79:682–692.
Ontaneda D, Tallantyre E, Kalincik T, et al. Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. Lancet Neurol 2019;18:973–980.
Seewann A, Kooi E‐J, Roosendaal SD, et al. Postmortem verification of MS cortical lesion detection with 3D DIR. Neurology 2012;78:302–308.
Madsen MAJ, Wiggermann V, Bramow S, et al. Imaging cortical multiple sclerosis lesions with ultra‐high field MRI. Neuroimage Clin 2021;32:102847.
Nelson F, Poonawalla A, Hou P, et al. 3D MPRAGE improves classification of cortical lesions in multiple sclerosis. Mult Scler 2008;14:1214–1219.
Sethi V, Yousry TA, Muhlert N, et al. Improved detection of cortical MS lesions with phase‐sensitive inversion recovery MRI. J Neurol Neurosurg Psychiatry 2012;83:877–882.
Beck ES, Sati P, Sethi V, et al. Improved visualization of cortical lesions in multiple sclerosis using 7T MP2RAGE. AJNR Am J Neuroradiol 2018;39:459–466.
Chang I, Kappos L, Giovannoni G, et al. Overall disability response score: an integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis. Mult Scler 2022;28:2263–2273.
Müller J, Cagol A, Lorscheider J, et al. Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: a systematic review. JAMA Neurol 2023;80:1232–1245.
Saccà F, Costabile T, Carotenuto A, et al. The EDSS integration with the brief international cognitive assessment for multiple sclerosis and orientation tests. Mult Scler 2017;23:1289–1296.
Andreopoulou G, Mercer TH, Enriquez JG, et al. Exercise‐induced changes in gait kinematics in multiple sclerosis with minimal neurological disability. Mult Scler Relat Disord 2021;47:102630.
Midaglia L, Mulero P, Montalban X, et al. Adherence and satisfaction of smartphone‐ and smartwatch‐based remote active testing and passive monitoring in people with multiple sclerosis: nonrandomized interventional feasibility study. J Med Internet Res 2019;21:e14863.
Bonzano L, Bove M, Sormani MP, et al. Subclinical motor impairment assessed with an engineered glove correlates with magnetic resonance imaging tissue damage in radiologically isolated syndrome. Eur J Neurol 2019;26:162–167.
D'Amico E, Haase R, Ziemssen T. Review: patient‐reported outcomes in multiple sclerosis care. Mult Scler Relat Disord 2019;33:61–66.
Veldhuijzen van Zanten J, Douglas MR, Ntoumanis N. Fatigue and fluctuations in physical and psychological wellbeing in people with multiple sclerosis: a longitudinal study. Mult Scler Relat Disord 2021;47:102602.
Rodgers J, Friede T, Vonberg FW, et al. The impact of smoking cessation on multiple sclerosis disease progression. Brain 2022;145:1368–1378.
Abdelhak A, Antweiler K, Kowarik MC, et al. Patient‐reported outcome parameters and disability worsening in progressive multiple sclerosis. Mult Scler Relat Disord 2024;81:105139.
Marrie RA, Leung S, Cutter GR, et al. Comparative responsiveness of the health utilities index and the RAND‐12 for multiple sclerosis. Mult Scler 2021;27:1781–1789.
Bayas A, Schuh K, Christ M. Self‐assessment of people with relapsing‐remitting and progressive multiple sclerosis towards burden of disease, progression, and treatment utilization‐results of a large‐scale cross‐sectional online survey (MS perspectives). Mult Scler Relat Disord 2022;68:104166.
University of California, San Francisco MS‐EPIC Team, Cree BA, Gourraud P‐A, et al. Long‐term evolution of multiple sclerosis disability in the treatment era. Ann Neurol 2016;80:499–510.
Longinetti E, Englund S, Burman J, et al. Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease‐modulating therapy. J Neurol Neurosurg Psychiatry 2024;95:134–141.
Brown JWL, Coles A, Horakova D, et al. Association of initial disease‐modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 2019;321:175–187.
Briggs FB, Gunzler DD, Ontaneda D, Marrie RA. Smokers with MS have greater decrements in quality of life and disability than non‐smokers. Mult Scler 2017;23:1772–1781.
Krause N, Derad C, vonGlasenapp B, et al. Association of health behaviour and clinical manifestation in early multiple sclerosis in Germany – baseline characteristics of the POWER@MS1 randomised controlled trial. Mult Scler Relat Disord 2023;79:105043.
Dobson R, Rice DR, D'hooghe M, et al. Social determinants of health in multiple sclerosis. Nat Rev Neurol 2022;18:723–734.
Giovannoni G, Ford HL, Schmierer K, et al. MS care: integrating advanced therapies and holistic management. Front Neurol 2023;14:1286122.
Beratto L, Bressy L, Agostino S, et al. The effect of exercise on mental health and health‐related quality of life in individuals with multiple sclerosis: a systematic review and meta‐analysis. Mult Scler Relat Disord 2024;83:105473.
Bruce JM, Cozart JS, Shook RP, et al. Modifying diet and exercise in multiple sclerosis (MoDEMS): a randomized controlled trial for behavioral weight loss in adults with multiple sclerosis and obesity. Mult Scler 2023;29:1860–1871.
Lysogorskaia E, Ivanov T, Mendalieva A, et al. Yoga vs physical therapy in multiple sclerosis: results of randomized controlled trial and the training protocol. Ann Neurosci 2023;30:242–250.
Giovannoni G, Butzkueven H, Dhib‐Jalbut S, et al. Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord 2016;9:S5–S48.
Marrie RA, Sormani MP, Apap Mangion S, et al. Improving the efficiency of clinical trials in multiple sclerosis. Mult Scler 2023;29:1136–1148.
McAdams M, Stankiewicz JM, Weiner HL, Chitnis T. Review of phase III clinical trials outcomes in patients with secondary progressive multiple sclerosis. Mult Scler Relat Disord 2021;54:103086.
Cruz Rivera S, Aiyegbusi OL, Piani Meier D, et al. The effect of disease modifying therapies on fatigue in multiple sclerosis. Mult Scler Relat Disord 2023;79:105065.
Andravizou A, Dardiotis E, Artemiadis A, et al. Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options. Auto Immun Highlights 2019;10:7.
Sima DM, Esposito G, Van Hecke W, et al. Health economic impact of software‐assisted brain MRI on therapeutic decision‐making and outcomes of relapsing‐remitting multiple sclerosis patients—a microsimulation study. Brain Sci 2021;11:1570.
Arnold DL, Fisher E, Brinar VV, et al. Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β‐1a in MS. Neurology 2016;87:1464–1472.